On October 28, 2024, Karthik Radhakrishnan, Chief Financial Officer of Monopar Therapeutics Inc (MNPR, Financial), bought 1,550 shares of the company, according to a recent SEC Filing. This transaction increased the insider's total holdings to 1,550 shares.
Monopar Therapeutics Inc is a biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's approach includes targeting advanced and metastatic stages of various cancers.
The shares were purchased at a price of $16.25 each, valuing the transaction at approximately $25,187.50. Following this transaction, the market cap of Monopar Therapeutics Inc stands at $51.645 million.
Over the past year, the insider transaction history at Monopar Therapeutics Inc shows a trend of more insider buying than selling. There have been five insider buys and zero insider sells. The insider, Karthik Radhakrishnan, has been active in the market, with a total of 1,550 shares purchased and zero shares sold.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further to understand the stock's current market position and potential future performance.
This insider buying activity could be a signal to investors about the insider’s confidence in the company's future prospects or undervaluation of the stock. However, investors should also consider other market factors and perform their own due diligence before making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
